[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493066":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":83,"collaborators":20,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":20,"enrollmentInfo":95,"targetDuration":20,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"ShiraTronics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Neurostimulation","EXPERIMENTAL","Neurostimulation will be delivered to target nerves.",[13],"Device: neurostimulator",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","neurostimulator","The ShiraTronics Migraine Therapy System",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Scientific Advisory Board","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Fred Ecklund","CONTACT","1-844-228-7330","fecklund@shiratronics.com",[32,48,59,71],{"facility":33,"status":34,"city":35,"state":36,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Genesis Research Services","RECRUITING","Broadmeadow","New South Wales","Australia","AU",{"type":40,"coordinates":41},"Point",[42,43],151.72849,-32.92371,{"lat":43,"lon":42},[46],{"name":20,"role":28,"phone":47,"phoneExt":20,"email":20},"+61 2 4985 1860",{"facility":49,"status":34,"city":50,"state":36,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Australian Medical Research","Hurstville",{"type":40,"coordinates":52},[53,54],151.10149,-33.9677,{"lat":54,"lon":53},[57],{"name":20,"role":28,"phone":58,"phoneExt":20,"email":20},"+61 (02) 9570 5550",{"facility":60,"status":34,"city":61,"state":62,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"CerCare","Wayville","South Australia",{"type":40,"coordinates":64},[65,66],138.59132,-34.94468,{"lat":66,"lon":65},[69],{"name":20,"role":28,"phone":70,"phoneExt":20,"email":20},"+61 410 567 855",{"facility":72,"status":34,"city":73,"state":74,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Paincare Perth","Perth","Western Australia",{"type":40,"coordinates":76},[77,78],115.8614,-31.95224,{"lat":78,"lon":77},[81],{"name":20,"role":28,"phone":82,"phoneExt":20,"email":20},"+61 8 9284 6005",{"type":84,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100493066","study-using-the-shiratronics-migraine-therapy-system-100493066",false,"NCT05700318","Study Using the ShiraTronics Migraine Therapy System","A Pilot Study Assessing Preliminary Safety and Efficacy of The ShiraTronics Migraine Therapy System in Relieving, Interrupting, and Preventing Chronic Migraine","RELIEV-CM","Inclusion Criteria:\n\n1. Participants who are 22 years of age or older.\n2. History of migraine ≥ 12 months.\n3. Participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation.\n4. Inadequate response to, unwilling, or contraindicated to Onabotulinumtoxin A and CGRP monoclonal antibodies therapy.\n5. Stable use of migraine medication.\n\nExclusion Criteria:\n\n1. Post-traumatic headache.\n2. Medication overuse headache.\n3. New daily persistent headache.\n4. Report experiencing unremitting, continuous headaches with no relief.\n5. Previously implanted neurostimulator to treat headache.\n6. History of cervical radiofrequency ablation or had any other intervention\u002Fdevice for migraine.","ALL","22 Years",{"count":96,"type":97},40,"ESTIMATED","INTERVENTIONAL",[100],"NA","The purpose of this pilot study is to assess the preliminary safety and efficacy of the ShiraTronics Migraine Therapy System in prophylactic treatment of patients with refractory chronic migraine.",[103],"Chronic Migraine, Headache","2024-07-14",{"date":106,"type":107},"2024-07-16","ACTUAL",{"date":109,"type":107},"2023-05-05",{"date":111,"type":97},"2025-03",{"name":5,"class":6},4]